Skip to main content

Table 2 Currently FDA approved and preclinical therapeutic targets in the translational pipeline targeting EMT-related pathways

From: The translational significance of epithelial-mesenchymal transition in head and neck cancer

Agent Type Target/MOA Combinational regimen Trial Clinical stage References
Cetuximab MAb EGFR-Selective Tyrosine Kinase Inhibitor Radiation; Cisplatin (Metastatic) Bonner; EXTREME FDA Approved 2006; 2008 (Metastatic) [5],[119]
PD173074 Small molecule FGFR1; Nonselective Tyrosine Kinase Inhibitor -- -- Preclinical [113]
Colecoxib Small molecule COX-2 Inhibitor -- -- Preclinical [69]
NS-398 Small molecule COX-2 Inhibitor -- -- Preclinical [69]
SC-91 Small molecule COX-2 Inhibitor -- -- Preclinical [69]
Trans RA Small molecule RAR agonist/TGFβ Antagonist -- -- Preclinical [115]
AZ64 Small molecule Trkβ; Nonselective Tyrosine Kinase Inhibitor Cisplatin -- Preclinical [67]
Bivatuzumab-DM1 MAb CD44v6-Maytansionoid Cytotoxin mertansine -- -- Phase 1 (discontinued) [120],[121]